| Purity: | 99 |
|---|---|
| Model Number: | 201530-41-8 |
| Brand Name: | NJBN STEROID |
| Grade Standard: | Medicine Grade |
| Type: | Vitamins, Amino Acids and Coenzymes |
| Place of Origin: | China (Mainland) |
| EINECS No.: | 201530-41-8 |
| MF: | C21H15N3O4 |
| Other Names: | Deferasirox |
| CAS No.: | 201530-41-8 |
| Sample: | Free |
| Market: | Worldwide |
Quick Details
Specifications
Factory of Deferasirox 201530-41-8 Deferasirox for Chelator
Product Name: Deferasirox
Synonyms: 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid;deferasirox;Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-;Deferasirox for research;4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic Acid;CGP-72670;Exjade;ICL-670
CAS: 201530-41-8
MF: C21H15N3O4
MW: 373.3615
Chemical Properties White to off-White Solid
Usage Orally active tridentate iron chelator
COA
Properties of deferasirox
Two deferasirox molecules binding iron
the half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which are subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
Product Name: Deferasirox
Synonyms: 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid;deferasirox;Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-;Deferasirox for research;4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic Acid;CGP-72670;Exjade;ICL-670
CAS: 201530-41-8
MF: C21H15N3O4
MW: 373.3615
Chemical Properties White to off-White Solid
Usage Orally active tridentate iron chelator
COA
| Items of analysis | Specification | Results |
| Appearance | Light yellow to off-white solid | Conforms |
| Identification | IR/HPLC | Conforms |
| Water | ≤0.2% | 0.12% |
| Impurity | Single impurity ≤ 0.1% | 0.05% |
| Purity | ≥99.5% | 99.68% |
| Conclusion | Qualified | |
Properties of deferasirox
Two deferasirox molecules binding iron
the half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which are subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
